The role of innate and adaptive immunity in parkinson's disease

Journal of Parkinson's Disease

Volumn 3, Issue 4, 2013, Pages 493-514

  Kannarkat, George T ^a   Boss, Jeremy M ^a   Tansey, Malú G ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Microbiology and Immunology Emory University School of Medicine ^*  (United States)

Author keywords

Adaptive immunity; Immune system; Immunomodulation; Inflammation; Lymphocytes; Parkinson's disease

Indexed keywords

ABATACEPT; ALPHA SYNUCLEIN ANTIBODY; ANTIBODY; BELATACEPT; COLCHICINE; CORTICOSTEROID; DOMINANT NEGATIVE INHIBITOR OF TUMOR NECROSIS FACTOR ALPHA INHIBITOR; GLATIRAMER; IMMUNOGLOBULIN; NATALIZUMAB; OKT 3; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; CELL COMPOSITION; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DEGENERATIVE DISEASE; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; FEVER; GENE EXPRESSION; GENE MUTATION; GRAFT REJECTION; HEADACHE; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOLOGY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; MICROGLIA; MULTIPLE SCLEROSIS; NAUSEA; NEWBORN HEMOLYTIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENICITY; PERIPHERAL NERVOUS SYSTEM; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ADAPTIVE IMMUNITY; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTES; PARKINSON'S DISEASE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; IMMUNITY, INNATE; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROGLIA; MUTATION; PARKINSON DISEASE; T-LYMPHOCYTES;

EID: 84898757532     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130250     Document Type: Review

References (193)

1. Chen JJ (2010) Parkinson's disease: Health-related quality of life, economic cost, and implications of early treatment. AJMC, S87-S93.
2. Henchcliffe C, & Severt WL (2011) Disease modification in Parkinson's disease. Drugs Aging, 28, 605-615.
3. Factor S, & Weiner W, Parkinson's Disease: Diagnosis and Clinical Management, Demos Medical Publishing.
4. Samii A, Nutt JG,&RansomBR(2004) Parkinson's disease. Lancet, 363, 1783-1793.
5. Lesage S, & Brice A (2009) Parkinson's disease: From monogenic forms to genetic susceptibility factors. Hum Mol Genet, 18, R48-R59.
6. Gelb DJ, Oliver E, & Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol, 56, 33-39.
7. Hawkes CH, Del Tredici K,&BraakH(2010)Atimeline for Parkinson's disease. Parkinsonism Relat Disord, 16, 79-84.
8. Brooks DJ (1998) The early diagnosis of Parkinson's disease. Ann Neurol, 44, S10-S18.
9. Ross OA (2013) A prognostic view on the application of individualized genomics in Parkinson's disease. Curr Genet Med Rep, 1, 52-57.
10. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM,&Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res, 1, 249-254.
11. Ballard PA, Tetrud JW, & Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases. Neurology, 35, 949-956.
12. Bove J, & Perier C (2012) Neurotoxin-based models of Parkinson's disease. Neuroscience, 211, 51-76.
13. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, & Rocca WA (2003) Head trauma preceding PD: A case-control study. Neurology, 60, 1610-1615.
14. Hernan MA, Takkouche B, Caamano-Isorna F, & Gestal-Otero JJ (2002)Ameta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol, 52, 276-284.
15. Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A, & Blair A (2010) Smoking duration, intensity, and risk of Parkinson disease. Neurology, 74, 878-884.
16. Chemaly RE, & Moussalli AS (2012) Parkinsonian syndrome as a complication of systemic lupus erythematosus. Report of a case and review of the literature. J Med Liban, 60, 103-105.
17. Li X, Sundquist J,&SundquistK(2012) Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: A nationwide epidemiological study from Sweden. Neurodgener Dis, 10, 277-284.
18. Rugbjerg K, Friis S, Ritz B, Schernhammer ES, Korbo L, & Olsen JH (2009) Autoimmune disease and risk for Parkinson disease: A population-based case-control study. Neurology, 73, 1462-1468.
19. Samii A, Etminan M,Wiens MO, & Jafari S (2009) NSAID use and the risk of Parkinson's disease: Systematic review and meta-analysis of observational studies. Drugs Aging, 26, 769-779.
20. Walker RH, Spiera H, Brin MF, & Olanow CW (1999) Parkinsonism associated with Sjögren's syndrome: Three cases and a reviewof the literature.Mov Disord, 14, 262-268.
21. Ravenholt RT, & Foege WH (1982) 1918 influenza, encephalitis lethargica, parkinsonism. Lancet, 2, 860-864.
22. Langan SM, Groves RW, & West J (2011) The relationship between neurological disease and bullous pemphigoid: A population-based case-control study. J Invest Dermatol, 131, 631-636.
23. Miman O, Kusbeci OY, Aktepe OC, & Cetinkaya Z (2010) The probable relation between Toxoplasma gondii and Parkinson's disease. Neurosci Lett, 475, 129-131.
24. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, & Ascherio A (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol, 60, 1059-1064.
25. Shlomchik MJ, & Weisel F (2012) Germinal center selection and the development of memory B and plasma cells. Immunol Rev, 247, 52-63.
26. Salmond RJ,&Zamoyska R (2011) The influence of mTOR on T helper cell differentiation and dendritic cell function. Eur J Immunol, 41, 2137-2141.
27. Sommer F,&Backhed F (2013) The gut microbiota-masters of host development and physiology. Nat Rev Microbiol, 11, 227-238.
28. Dauer W, & Przedborski S (2003) Parkinson's disease: Mechanisms and models. Neuron, 39, 889-909.
29. McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, & Carvey PM (2001) Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol, 169, 219-230.
30. Block ML, Zecca L, & Hong JS (2007) Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat Rev Neurosci, 8, 57-69.
31. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, & Park DS (2007) Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci, 27, 3328-3337.
32. Tansey MG, & Goldberg MS (2010) Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis, 37, 510-518.
33. Lawson LJ, Perry VH, Dri P, & Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience, 39, 151-170.
34. Herrera AJ, Castano A, Venero JL, Cano J, & Machado A (2000) The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 7, 429-447.
35. Castano A, Herrera AJ, Cano J, & Machado A (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem, 70, 1584-1592.
36. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, & Liu B (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. J Neurochem, 81, 1285-1297.
37. Mogi M, Harada M,KondoT, Riederer P, Inagaki H, Minami M, & Nagatsu T (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factoralpha are elevated in the brain from parkinsonian patients. Neurosci Letter, 180, 147-150.
38. Mogi M, Harada M, Kondo T, Riederer P, & Nagatsu T (1995) Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J Neural Transm Park Dis Dement Sect, 9, 87-92.
39. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, & Riederer P (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Letter, 202, 17-20.
40. Yamada T, McGeer PL, & McGeer EG (1992) Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol, 84, 100-104.
41. Koziorowski D, Tomasiuk R, Szlufik S, & Friedman A (2012) Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine, 60, 762-766.
42. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, & Czlonkowska A (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol, 156, 50-61.
43. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, & Czlonkowski A (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration, 5, 137-143.
44. Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, & Nagatsu T (2000) Increase in level of tumor necrosis factoralpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci Lett, 289, 165-168.
45. Theodore S, Cao S, McLean PJ, & Standaert DG (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol, 67, 1149-1158.
46. Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, Effros RB, & Chesselet MF (2012) Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol, 237, 318-334.
47. Tofaris GK, Garcia Reitbock P, Humby T, Lambourne SL, O'Connell M, Ghetti B, Gossage H, Emson PC, Wilkinson LS, Goedert M, & Spillantini MG (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): Implications for Lewy body disorders. J Neurosci, 26, 3942-3950.
48. Emmer KL, Waxman EA, Covy JP, & Giasson BI (2011) E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem, 286, 35104-35118.
49. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, & Price DL (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 - Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad SciUS A, 99, 8968-8973.
50. Miller RM, Kiser GL, Kaysser-Kranich T, Casaceli C, Colla E, Lee MK, Palaniappan C,&FederoffHJ (2007)Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Exp Neurol, 204, 421-432.
51. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J,Willemsen AT, & Hendrikse NH (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol, 57, 176-179.
52. Pisani V, Stefani A, Pierantozzi M, Natoli S, Stanzione P, Franciotta D, & Pisani A (2012) Increased bloodcerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J Neuroinflammation, 9, 188.
53. Farkas E, De Jong GI, deVos RA, Jansen Steur EN,&Luiten PG (2000) Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol, 100, 395-402.
54. Faucheux BA, Bonnet A-M, Agid Y, & Hirsch EC (1999) Blood vessels change in the mesencephalon of patients with Parkinson's disease. The Lancet, 353, 981-982.
55. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-BerthatV, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, & Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest, 119, 182-192.
56. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, & McGeer PL (2006) Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol, 197, 275-283.
57. Croisier E, Moran LB, Dexter DT, Pearce RK, & Graeber MB (2005) Microglial inflammation in the parkinsonian substantia nigra: Relationship to alpha-synuclein deposition. J Neuroinflammation, 2, 14.
58. Kim SU, & de Vellis J (2005) Microglia in health and disease. J Neurosci Res, 81, 302-313.
59. Aloisi F (2001) Immune function of microglia. Glia, 36, 165-179.
60. Klegeris A, Pelech S, Giasson BI, Maguire J, Zhang H, McGeer EG, & McGeer PL (2008) Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging, 29, 739-752.
61. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, & Federoff HJ (2008) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging, 29, 1690-1701.
62. Su X, Federoff HJ, & Maguire-Zeiss KA (2009) Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res, 16, 238-254.
63. Wilms H, Rosenstiel P, Romero-Ramos M, Arlt A, Schäfer H, Seegert D, Kahle PJ, Odoy S, Claasen JH, Holzknecht C, Brandenburg LO, Deuschl G, Schreiber S, Kirik D,&Lucius R (2009) Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. Int J Immunopathol Pharmacol, 22, 897-909.
64. Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, Kim WK, Junn E, & Kim HS (2010) Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol, 185, 615-623.
65. Couch Y, Alvarez-Erviti L, Sibson NR, Wood MJ, & Anthony DC (2011) The acute inflammatory response to intranigral alpha-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation, 8, 166.
66. Marin-Teva JL, Cuadros MA,Martin-Oliva D,&Navascues J (2011) Microglia and neuronal cell death. Neuron Glia Biol, 7, 25-40.
67. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, & Gendelman HE (2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol, 184, 2261-2271.
68. Waldburger JM, Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M, Landmann S, & Reith W (2000) Lessons from the bare lymphocyte syndrome: Molecular mechanisms regulating MHC class II expression. Immunol Rev, 178, 148-165.
69. Luckheeram RV, Zhou R, Verma AD, & Xia B (2012) CD4(+)T cells: Differentiation and functions. Clin Dev Immuno, 2012, 925135.
70. Marsh SG, & System WHONCfFotH (2013) Nomenclature for factors of the HLA system, update December 2012. Tissue Antigens, 81, 253-257.
71. Yamane H, & Paul WE (2012) Cytokines of the gamma(c) family control CD4+ T cell differentiation and function. Nat Immunol, 13, 1037-1044.
72. McGeer PL, Itagaki S, Boyes BE, & McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38, 1285-1291.
73. McGeer PL, Itagaki S, & McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol, 76, 550-557.
74. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, & Hashizume Y (2003) Distribution of major histocom patibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol, 106, 518-526.
75. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA,& Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol, 46, 598-605.
76. McGeer PL, Schwab C, Parent A, & Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol, 54, 599-604.
77. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza YPM, Fernandez-Barreiro A, Hirsch EC,&Herrero MT (2004) Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia, 46, 402-409.
78. Vázquez-Claverie M, Garrido-Gil P, San SebastiánW, Izal-Azcárate A, Belzunegui S, Marcilla I, López B, & Luquin MR (2009) Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys. J Neuropathol Exp Neurol, 68, 977-984.
79. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, OertelW, Banati RB,&Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis, 21, 404-412.
80. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, & Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol, 57, 168-175.
81. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J,Yearout D, Kay DM, DohenyKF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK,Nutt J, Factor SA,&PayamiH(2010)Commongenetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet, 42, 781-785.
82. Guo Y, Deng X, Zheng W, Xu H, Song Z, Liang H, Lei J, Jiang X, Luo Z, & Deng H (2011) HLA rs3129882 variant in Chinese Han patients with late-onset sporadic Parkinson disease. Neurosci Lett, 501, 185-187.
83. Ahmed I, Tamouza R, Delord M, Krishnamoorthy R, Tzourio C, Mulot C, Nacfer M, Lambert JC, Beaune P, Laurent-Puig P, Loriot MA, Charron D, & Elbaz A (2012) Association between Parkinson's disease and the HLADRB1 locus. Mov Disord, 27, 1104-1110.
84. Hill-Burns EM, Factor SA, Zabetian CP, Thomson G, & Payami H (2011) Evidence for more than one Parkinson's disease-associated variant within the HLA region. PLoS One, 6, e27109.
85. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, & Toda T (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet, 41, 1303-1307.
86. International Parkinson Disease Genomics C, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simon-Sanchez J, Schulte C, Lesage S, Sveinbjornsdottir S, Stefansson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, & Wood NW (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet, 377, 641-649.
87. Sun C, Wei L, Luo F, Li Y, Li J, Zhu F, Kang P, Xu R, Xiao L, Liu Z, & Xu P (2012) HLA-DRB1 alleles are associated with the susceptibility to sporadic Parkinson's disease in Chinese Han population. PLoS One, 7, e48594.
88. Fiszer U, Mix E, Fredrikson S, Kostulas V, & Link H (1994) Parkinson's disease and immunological abnormalities: Increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+T cells in peripheral blood. Acta Neurol Scand, 90, 160-166.
89. Botta-Orfila T, Sanchez-Pla A, Fernandez M, Carmona F, Ezquerra M, & Tolosa E (2012) Brain transcriptomic profiling in idiopathic and LRRK2-associated Parkinson's disease. Brain Res, 1466, 152-157.
90. Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Juzwiak S, Kurzawski G, Tan EK, & Drozdzik M (2007) CARD15 variants in patients with sporadic Parkinson's disease. Neurosci Res, 57, 473-476.
91. Dobbs SM, Dobbs RJ, Weller C, & Charlett A (2000) Link between Helicobacter pylori infection and idiopathic parkinsonism. Med Hypotheses, 55, 93-98.
92. Woulfe J, Hoogendoorn H, Tarnopolsky M, & Muñoz DG (2000) Monoclonal antibodies against Epstein-Barr virus cross-react with alpha-synuclein in human brain. Neurology, 55, 1398-1401.
93. Jang H, Boltz D, McClaren J, Pani AK, Smeyne M, Korff A, Webster R, & Smeyne RJ (2012) Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice. J Neurosci, 32, 1545-1559.
94. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, Webster R, & Smeyne RJ (2009) Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A, 106, 14063-14068.
95. Shoji H, Watanabe M, Itoh S, Kuwahara H, & Hattori F (1993) Japanese encephalitis and parkinsonism. J Neurol, 240, 59-60.
96. Ogata A, Tashiro K, Nukuzuma S, Nagashima K, & Hall WW (1997) A rat model of Parkinson's disease induced by Japanese encephalitis virus. J Neurovirol, 3, 141-147.
97. Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, Cron RQ, Shacka JJ, Raman C, & Standaert DG (2013) MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci, 33, 9592-9600.
98. Cose S, Brammer C, Khanna KM, Masopust D, & Lefrancois L (2006) Evidence that a significant number of naive T cells enter non-lymphoid organs as part of a normal migratory pathway. Eur J Immunol, 36, 1423-1433.
99. van der Most RG, Murali-Krishna K, & Ahmed R (2003) Prolonged presence of effector-memory CD8 T cells in the central nervous system after dengue virus encephalitis. Int Immunol, 15, 119-125.
100. JoffreOP, Segura E, Savina A,&Amigorena S (2012) Crosspresentation by dendritic cells. Nat Rev Immunol, 12, 557-569.
101. Bas J, Calopa M, Mestre M, Mollevi DG, Cutillas B, Ambrosio S, & Buendia E (2001) Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol, 113, 146-152.
102. Stevens CH, Rowe D, Morel-Kopp MC, Orr C, Russell T, Ranola M,Ward C,&HallidayGM(2012) ReducedThelper and B lymphocytes in Parkinson's disease. J Neuroimmunol, 252, 95-99.
103. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, & Yamada T (2005) Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord, 11, 493-498.
104. Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM,Torres-Russotto DR, Meza JL, Santamaria PM, Bertoni JM, Murman DL, Ali HH, Standaert DG, Mosley RL, & Gendelman HE (2012) CD4+ regulatory and effector/ memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol, 7, 927-938.
105. Calopa M, Bas J, Callen A, & Mestre M (2010) Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis, 38, 1-7.
106. Niwa F, Kuriyama N, Nakagawa M, & Imanishi J (2012) Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr Gerontol Int, 12, 102-107.
107. Fiszer U, Fredrikson S, Mix E, Olsson T, & Link H (1996) V region T cell receptor repertoire in Parkinson's disease. Acta Neurol Scand, 93, 25-29.
108. Alberio T, Pippione AC, Zibetti M, Olgiati S, Cecconi D, Comi C, Lopiano L, & FasanoM(2012) Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease. Sci Rep, 2, 953.
109. Migliore L, Petrozzi L, Lucetti C, Gambaccini G, Bernardini S, Scarpato R, Trippi F, Barale R, Frenzilli G, Rodilla V, & Bonuccelli U (2002) Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology, 58, 1809-1815.
110. Cornetta T, Palma S, Aprile I, Padua L, Tonali P, Testa A, & Cozzi R (2009) Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease. Cell Biol Toxicol, 25, 321-330.
111. Blandini F, Mangiagalli A, Cosentino M, Marino F, Samuele A, Rasini E, Fancellu R, Martignoni E, Riboldazzi G, Calandrella D, Frigo GM,&NappiG(2003) Peripheral markers of apoptosis in Parkinson's disease: The effect of dopaminergic drugs. Ann N Y Acad Sci, 1010, 675-678.
112. Lira A, Kulczycki J, Slack R, Anisman H, & Park DS (2011) Involvement of the Fc gamma receptor in a chronic N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of dopaminergic loss. J Biol Chem, 286, 28783-28793.
113. Fleisher TA, & Oliveira JB (2012) Monogenic defects in lymphocyte apoptosis. Curr Opin Allergy Clin Immunol, 12, 609-615.
114. Choi C, & Benveniste EN (2004) Fas ligand/Fas system in the brain: Regulator of immune and apoptotic responses. Brain Research Reviews, 44, 65-81.
115. Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, Nemachek C, Ciborowski P, Przedborski S, Mosley RL, & Gendelman HE (2008) Nitrated alphasynuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One, 3, e1376.
116. Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, Poewe W, Reindl M, Oertel WH, Noelker C, Bacher M, & Dodel R (2013) Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology, 80, 169-175.
117. Han M, Nagele E, DeMarshall C, Acharya N, & Nagele R (2012) Diagnosis of Parkinson's disease based on diseasespecific autoantibody profiles in human sera. PLoS One, 7, e32383.
118. Derecki NC, Cardani AN,Yang CH, QuinniesKM,Crihfield A, Lynch KR, & Kipnis J (2010) Regulation of learning and memory by meningeal immunity: A key role for IL-4. J Exp Med, 207, 1067-1080.
119. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E,&Aloisi F (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol, 14, 164-174.
120. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, Burmester GR, Lipsky PE, & Dorner T (2002) Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum, 46, 2160-2171.
121. Fekete A, Soos L, Szekanecz Z, Szabo Z, Szodoray P, Barath S, & Lakos G (2007) Disturbances in B-and T-cell homeostasis in rheumatoid arthritis: Suggested relationships with antigen-driven immune responses. J Autoimmun, 29, 154-163.
122. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, Fleisher TA, Wilson M, Goldbach-Mansky R, & Lipsky PE (2009) Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther, 11, R84.
123. Carvey PM, McRae A, Lint TF, Ptak LR, Lo ES, Goetz CG, & Klawans HL (1991) The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology, 41, 53-58.
124. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, Papadimitriou A, Kalofoutis A, &BuchmanVL(2007) Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem, 101, 749-756.
125. Orr CF, Rowe DB, Mizuno Y, Mori H, & Halliday GM (2005) A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain, 128, 2665-2674.
126. Chen S, LeWD,Xie WJ, AlexianuME,Engelhardt JI, Siklos L, & Appel SH (1998) Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol, 55, 1075-1080.
127. He Y, Le W-D, & Appel SH (2002) Role of Fcγ Receptors in Nigral Cell Injury Induced by Parkinson Disease Immunoglobulin Injection into Mouse Substantia Nigra. Experimental Neurology, 176, 322-327.
128. Cao S, Theodore S, & Standaert DG (2010) Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Mol Neurodegener, 5, 42.
129. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, & Lee SJ (2012) Antibody-aided clearance of extracellular alpha-synuclein prevents cell-tocell aggregate transmission. J Neurosci, 32, 13454-13469.
130. Singleton AB, Farrer MJ, & Bonifati V (2013) The genetics of Parkinson's disease: Progress and therapeutic implications. Mov Disord, 28, 14-23.
131. Trinh J, & Farrer M (2013) Advances in the genetics of Parkinson disease. Nat Rev Neurol, 9, 445-454.
132. Houlden H, & Singleton AB (2012) The genetics and neuropathology of Parkinson's disease. Acta Neuropathol, 124, 325-338.
133. Shin EC, Cho SE, Lee DK, Hur MW, Paik SR, Park JH, & Kim J (2000) Expression patterns of alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental stages. Mol Cells, 10, 65-70.
134. Su AI,Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, & Hogenesch JB (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A, 101, 6062-6067.
135. Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, Hodge CL, Haase J, Janes J, Huss JW, 3rd, & Su AI (2009) BioGPS:Anextensible and customizable portal for querying and organizing gene annotation resources. Genome Biol, 10, R130.
136. Austin SA, Floden AM, Murphy EJ, & Combs CK (2006) Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci, 26, 10558-10563.
137. Austin SA, Rojanathammanee L, Golovko MY, Murphy EJ, & Combs CK (2011) Lack of alpha-synuclein modulates microglial phenotype in vitro. Neurochem Res, 36, 994-1004.
138. Tanji K, Mori F, Imaizumi T, Yoshida H, Matsumiya T, TamoW, Yoshimoto M, Odagiri H, Sasaki M, Takahashi H, Satoh K, & Wakabayashi K (2002) Upregulation of alphasynuclein by lipopolysaccharide and interleukin-1 in human macrophages. Pathol Int, 52, 572-577.
139. Alessandri C, Barbati C, Vacirca D, Piscopo P, Confaloni A, Sanchez M, Maselli A, Colasanti T, Conti F, Truglia S, Perl A, Valesini G, Malorni W, Ortona E, & PierdominiciM( 2012) T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J, 26, 4722-4732.
140. Lu JV, & Walsh CM (2012) Programmed necrosis and autophagy in immune function. Immunol Rev, 249, 205-217.
141. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW,Meitinger T, Strom TM, Wszolek ZK, & Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601-607.
142. Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, RacetteBA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, HuskeyKW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, & Myers RH (2008) The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: The GenePD study. BMC Med, 6, 32.
143. Goldwurm S, Zini M, Mariani L, Tesei S, Miceli R, Sironi F, Clementi M, Bonifati V, & Pezzoli G (2007) Evaluation of LRRK2 G2019S penetrance: Relevance for genetic counseling in Parkinson disease. Neurology, 68, 1141-1143.
144. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kruger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, & Gasser T (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet, 41, 1308-1312.
145. Westerlund M, Belin AC, Anvret A, Bickford P, Olson L, &GalterD(2008) Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease. Neuroscience, 152, 429-436.
146. Galter D,Westerlund M, Carmine A, Lindqvist E, SydowO, & Olson L (2006) LRRK2 expression linked to dopamineinnervated areas. Ann Neurol, 59, 714-719.
147. Melrose H, Lincoln S, Tyndall G, Dickson D, & Farrer M (2006) Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience, 139, 791-794.
148. Taymans JM, Van den Haute C, & Baekelandt V (2006) Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem, 98, 951-961.
149. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, & Dawson TM (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A, 102, 16842-16847.
150. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL,&DawsonTM (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet, 16, 223-232.
151. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, & Cookson MR (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis, 23, 329-341.
152. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, & Ross CA (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci, 9, 1231-1233.
153. Lee BD, Shin JH, VanKampen J, Petrucelli L,West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL, & Dawson TM (2010) Inhibitors of leucinerich repeat kinase-2 protect against models of Parkinson's disease. Nat Med, 16, 998-1000.
154. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, BogdanovM, Przedborski S, BealMF, Burke RE, & Li C (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci, 12, 826-828.
155. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, & Cai H (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron, 64, 807-827.
156. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, & Yue Z (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci, 30, 1788-1797.
157. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ, Moore DJ, Dawson TM, Dawson VL, Chiosis G, Cookson MR, & Cai H (2008) The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci, 28, 3384-3391.
158. Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, Venderova K, Girardin SE, Bulman DE, Scherzer CR, LaVoie MJ, Gris D, Park DS, Angel JB, Shen J, Philpott DJ, & Schlossmacher MG (2011) Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm, 118, 795-808.
159. Miklossy J, Arai T, Guo JP, Klegeris A,Yu S, McGeer EG,& McGeer PL (2006) LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol, 65, 953-963.
160. Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, Korzenik JR, Rioux JD, Daly MJ, Xavier RJ, & Podolsky DK (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol, 185, 5577-5585.
161. Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, & West AB (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci, 32, 1602-1611.
162. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Consortium NIG, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, MniM, Rutgeerts P,Van Gossum A, Zelenika D, Franchimont D, Hugot JP, deVos M, Vermeire S, Louis E, Belgian-French IBDC,WellcomeTrust Case Control C, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M,&DalyMJ(2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet, 40, 955-962.
163. Zhang FR, HuangW, Chen SM, Sun LD, Liu H, Li Y, Cui Y, Yan XX, Yang HT, Yang RD, Chu TS, Zhang C, Zhang L, Han JW, Yu GQ, Quan C, Yu YX, Zhang Z, Shi BQ, Zhang LH, Cheng H,Wang CY, Lin Y, Zheng HF, Fu XA, Zuo XB, Wang Q, Long H, Sun YP, Cheng YL, Tian HQ, Zhou FS, Liu HX, Lu WS, He SM, Du WL, Shen M, Jin QY, Wang Y, Low HQ, Erwin T, Yang NH, Li JY, Zhao X, Jiao YL, Mao LG, Yin G, Jiang ZX, Wang XD, Yu JP, Hu ZH, Gong CH, Liu YQ, Liu RY, Wang DM, Wei D, Liu JX, Cao WK, Cao HZ, Li YP, Yan WG, Wei SY, Wang KJ, Hibberd ML, Yang S, Zhang XJ,&Liu JJ (2009) Genomewide association study of leprosy. N Engl J Med, 361, 2609-2618.
164. Liu Z, Lee J, Krummey S, Lu W, Cai H, & Lenardo MJ (2011) The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol, 12, 1063-1070.
165. Bonifati V (2012) Autosomal recessive parkinsonism. Parkinsonism & Related Disorders, 18, S4-S6.
166. Walden H, & Martinez-Torres RJ (2012) Regulation of Parkin E3 ubiquitin ligase activity. Cell Mol Life Sci, 69, 3053-3067.
167. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, & Suzuki T (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet, 25, 302-305.
168. Narendra D, Tanaka A, Suen DF, & Youle RJ (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol, 183, 795-803.
169. Vincow ES, Merrihew G, Thomas RE, Shulman NJ, Beyer RP, MacCoss MJ, & Pallanck LJ (2013) The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc Natl Acad Sci U S A, 110, 6400-6405.
170. Alves da Costa C, & Checler F (2012) Parkin: Much More than A Simple Ubiquitin Ligase. Neurodgener Dis, 10, 49-51.
171. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF,Maidment NT, Levine MS, & Shen J (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem, 278, 43628-43635.
172. Zhu XR, Maskri L, Herold C, Bader V, Stichel CC, Gunturkun O, & Lubbert H (2007) Non-motor behavioural impairments in parkin-deficient mice. Eur J Neurosci, 26, 1902-1911.
173. Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, Hartley M, Trevino I, O'Brien DE, Casey B, Goldberg MS, & Tansey MG (2008) Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci, 28, 10825-10834.
174. Tran TA, Nguyen AD, Chang J, Goldberg MS, Lee JK, & Tansey MG (2011) Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PLoS One, 6, e23660.
175. MiraMT, Alcais A, Nguyen VT,Moraes MO, Di Flumeri C, Vu HT,Mai CP, Nguyen TH, Nguyen NB, Pham XK, Sarno EN, Alter A, Montpetit A, Moraes ME,Moraes JR, Dore C, Gallant CJ, Lepage P, Verner A, Van De Vosse E, Hudson TJ, Abel L, & Schurr E (2004) Susceptibility to leprosy is associated with PARK2 and PACRG. Nature, 427, 636-640.
176. Ali S, Vollaard AM,Widjaja S, Surjadi C, van de Vosse E,& van Dissel JT (2006) PARK2/PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever. Clin Exp Immunol, 144, 425-431.
177. Manzanillo PS, Ayres JS, Watson RO, Collins AC, Souza G, Rae CS, Schneider DS, Nakamura K, Shiloh MU, & Cox JS (2013) The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature, 501, 512-516.
178. Boska MD, Lewis TB, Destache CJ, Benner EJ, Nelson JA, Uberti M, Mosley RL, & Gendelman HE (2005) Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. J Neurosci, 25, 1691-1700.
179. Johnston J, & So TY (2012) First-line disease-modifying therapies in paediatric multiple sclerosis: A comprehensive overview. Drugs, 72, 1195-1211.
180. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, & Gendelman HE (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A, 101, 9435-9440.
181. Gendelman H (2013) In Clinical Trials. Gov, National Library of Medicine.
182. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE,&TanseyMG(2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci, 26, 9365-9375.
183. McCoyMK, Ruhn KA,Martinez TN, McAlpine FE, Blesch A, & Tansey MG (2008) Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther, 16, 1572-1579.
184. Harms AS, Barnum CJ, Ruhn KA, Varghese S, Trevino I, Blesch A,&TanseyMG (2011) Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol Ther, 19, 46-52.
185. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, & Schenk D (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron, 46, 857-868.
186. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, & Schenk D (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One, 6, e19338.
187. Salama M, Ellaithy A, Helmy B, El-Gamal M, Tantawy D, Mohamed M, Sheashaa H, Sobh M, & Arias-Carrión O (2012) Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease. CNS Neurol Disord Drug Targets, 11, 836-843.
188. Yao S, Zhu Y, & Chen L (2013) Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov, 12, 130-146.
189. Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, & Charpentier B (2010) Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation, 90, 1528-1535.
190. Rudick R, Polman C, Clifford D, Miller D, & Steinman L (2013) Natalizumab: Bench to bedside and beyond. JAMA Neurol, 70, 172-182.
191. Park TS, Rosenberg SA,&Morgan RA(2011) Treating cancer with genetically engineered T cells. Trends Biotechnol, 29, 550-557.
192. Furtado J, & Isenberg DA (2013) B cell elimination in systemic lupus erythematosus. Clin Immunol, 146, 90-103.
193. Schwab I, & Nimmerjahn F (2013) Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat Rev Immunol, 13, 176-189.